Engineered virus takes on liver cancer when standard treatment fails
NCT ID NCT01387555
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This trial investigates whether JX-594 (Pexa-Vec), a virus modified to attack cancer cells and boost the immune system, combined with best supportive care, can help people with advanced liver cancer live longer. The study enrolls adults whose liver cancer has progressed or who could not tolerate the standard drug sorafenib. Participants are randomly assigned to receive either the virus therapy plus supportive care or supportive care alone, and their survival is compared.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JX-594 (Pexa-Vec) – a modified virus designed to infect and destroy cancer cells and stimulate the immune system
- What this could lead to
- If successful, this could provide a new treatment option for people with advanced liver cancer who have stopped responding to standard therapy, potentially extending survival.
- What could go wrong
- This is a Phase 2 trial with a relatively small number of participants. The virus-based therapy may cause flu-like symptoms or other side effects, and it is not yet proven to improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, 138-736, South Korea
-
Billings Clinic
Billings, Montana, United States
-
CHU d'Estaing
Clermont-Ferrand, Auvergne, 63003, France
-
California Pacific Medical Center
San Francisco, California, United States
-
Centre Hospitalier Universitaire Hôpital Saint André
Bordeaux, Aquitaine, 33000, France
-
Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
Gabrail Cancer Center
Canton, Ohio, United States
-
Hôpital Purpan
Toulouse, Midi-Pyrenees, 31059, France
-
Hôpital Saint Antoine, CPP Ile de France V
Paris, Île-de-France Region, 75571, France
-
Hôpital de la Croix Rousse
Lyon, Auvergne-Rhône-Alpes, 69317, France
-
Hôpitaux Universitaires de Strasbourg - Hôpital Civil
Strasbourg, Alsace, 67091, France
-
Johannes Gutenberg-Universität Mainz
Mainz, Rhineland-Palatinate, 55131, Germany
-
Juravinski Cancer Centre
Hamilton, Ontario, Canada
-
Klinikum Rechts der Isar der Technischen Universität München
München, Bavaria, 81675, Germany
-
Korea University Ansan Hospital
Ansan-si, Gyeonggi-do, 425-707, South Korea
-
Korea University Guro Hospital
Seoul, South Korea
-
Kyungpook National University Hospital
Daegu, South Korea
-
Medizinische Hochschule Hannover
Hanover, Lower Saxony, 30625, Germany
-
Montefiore Medical Center
The Bronx, New York, United States
-
Moores University of California San Diego Cancer Center
La Jolla, California, 92093, United States
-
National Cheng-Kung University Hospital
Tainan, Taiwan
-
National Taiwan University Hospital
Taipei, Taiwan
-
Ottawa Hopsital Research Institute
Ottawa, Ontario, Canada
-
Pusan National University Hospital
Pusan, South Korea
-
Pusan National University Yangsan Hospital
Yangsan, South Korea
-
Queen Mary Hospital
Hong Kong, Hong Kong
-
Saint Joseph's Hospital
Paterson, New Jersey, United States
-
Samsung Medical Center
Seoul, South Korea
-
Seoul National University Hospital
Seoul, South Korea
-
Severance Hospital,Yonsei University Health System
Seoul, South Korea
-
Stanford Hospital and Clinics
Stanford, California, United States
-
Taipei Veterans General Hospital
Taipei, Taiwan
-
The Methodist Hospital Department of Surgery
Houston, Texas, 77030, United States
-
University Hospitals Case Medical Center
Cleveland, Ohio, United States
-
University of Alberta
Edmonton, Alberta, T6G 2B7, Canada
-
University of British Columbia
Vancouver, British Columbia, Canada
-
University of Chicago Medical Center
Chicago, Illinois, United States
-
Universitätsklinikum Hamburg-Eppendorf
Hamburg, 20246, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer vaccine prime the body to better fight liver tumors?
- Training the immune system to hunt down leftover liver cancer cells
- A made-to-order DNA vaccine takes aim at liver cancer's return
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Could a genetic marker guide future cancer therapies in taiwan?
- Can a tumor-zapping procedure also wake up the immune system?